Grant: Project Grant
McMaster University
$816,255.00
Targeting the heterogeneity of cancer with dual-specific T cells and oncolytic vaccines
FY 2016-17
Summary
Given their ability to circulate throughout the body and kill tumor cells, white blood cells are an attractive weapon in the fight against cancer. Cell therapy is a cancer treatment where patients are infused with large numbers of white blood cells that have been optimized to fight their cancer. Recent clinical trials have demonstrated that infusion of white blood cells can lead to complete regression of advanced leukemia and melanoma, diseases that were previously untreatable. We have recently developed a virus-based vaccine platform that can dramatically amplify transferred white blood cells and enhance their localization and functionality in the tumor bed. We believe that combination of adoptive cell transfer and viral vaccines will create a broadly effective therapy for different solid tumors and metastases.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
356266
Name
Wan Yonghong
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Targeting the heterogeneity of cancer with dual-specific T cells and oncolytic vaccines
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$816,255
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Adoptive T Cell Therapy; Cancer Immunotherapy; Cancer Vaccines; Oncolytic Viruses
Abstract
Given their ability to circulate throughout the body and kill tumor cells, white blood cells are an attractive weapon in the fight against cancer. Cell therapy is a cancer treatment where patients are infused with large numbers of white blood cells that have been optimized to fight their cancer. Recent clinical trials have demonstrated that infusion of white blood cells can lead to complete regression of advanced leukemia and melanoma, diseases that were previously untreatable. We have recently developed a virus-based vaccine platform that can dramatically amplify transferred white blood cells and enhance their localization and functionality in the tumor bed. We believe that combination of adoptive cell transfer and viral vaccines will create a broadly effective therapy for different solid tumors and metastases.
Competitiondate
201610
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Wan, Yonghong
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $816,255~ $0~
